News

Press Releases

Year: 2010 | 2009 | 2008

September 1, 2010	Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC
August 30, 2010	Genzyme Confirms Receipt of Unsolicited Proposal
August 23, 2010	Two-Year Data from Phase 2 Trial of Genzyme’s Eliglustat Tartrate for Gaucher Disease To Be Published in the Journal Blood
August 4, 2010	Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen
July 27, 2010	Genzyme Encouraged by CMS Decision to Delay Oral Drug Inclusion in Dialysis Patient Benefit
July 21, 2010	Genzyme Reports Financial Results for the Second Quarter of 2010
June 18, 2010	Genzyme Announces Accelerated Share Repurchase
June 16, 2010	Shareholders Re-Elect All Members of Genzyme’s Board of Directors
June 15, 2010	Genzyme Prices Private Senior Notes Offerings
June 14, 2010	Genzyme’s Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA
June 9, 2010	Genzyme and Carl Icahn Reach Agreement
June 7, 2010	Dennis Fenton Nominated for Election to Genzyme’s Board of Directors
May 25, 2010	Genzyme Receives FDA Approval for Lumizyme for Pompe Disease
May 24, 2010	Genzyme Announces Final Terms of FDA Consent Decree
May 6, 2010	Genzyme Announces $2 Billion Stock Repurchase
April 21, 2010	Genzyme Reports Financial Results for the First Quarter of 2010
April 15, 2010	Genzyme Study of Myozyme Treatment for Pompe Disease Published in New England Journal of Medicine
April 15, 2010	Ralph Whitworth Elected to Genzyme’s Board of Directors
April 14, 2010	Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically-Active Disease
April 8, 2010	Genzyme Sets June 16 Date for Annual Meeting of Shareholders
March 31, 2010	Genzyme to Host Investor Event on Its Manufacturing Operations
March 30, 2010	Genzyme Creates Chief Operating Officer Position
March 24, 2010	Genzyme Announces FDA Enforcement Action Regarding Allston Plant
March 15, 2010	Mipomersen Phase 3 Study in HoFH Patients Featured in The Lancet
March 3, 2010	PTC Therapeutics and Genzyme Corporation Announce Preliminary Results from the Phase 2b Clinical Trial of Ataluren for Nonsense Mutation Duchenne/Becker Muscular Dystrophy
February 22, 2010	Genzyme Receives Notice of Icahn Partners’ Nomination of Directors
February 17, 2010	Genzyme Reports Financial Results for Fourth Quarter of 2009 and Full Year
February 11, 2010	Two-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Continued Improvement Across All Endpoints
February 10, 2010	Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint
February 3, 2010	Scott Canute Joins Genzyme to Head Manufacturing and Corporate Operations
January 29, 2010	Genzyme Strengthens Role of Board’s Lead Independent Director
January 28, 2010	Genzyme Adopts New Incentive Compensation Plans for Senior Executives
January 21, 2010	Genzyme’s Lumizyme BLA Receives Six-Month FDA Review
January 12, 2010	Genzyme Reports Fourth-Quarter Revenue
January 8, 2010	Industry Veteran Ron Branning Joins Genzyme to Lead Global Product Quality
January 7, 2010	Genzyme and Relational Investors Enter Into Mutual Cooperation Agreement

Terms and Conditions of Use | Privacy Policy | © 2002-2010 Genzyme Corporation. All rights reserved.